Eye clinics face an increasing influx of patients with tear film related problems or with ophthalmic conditions that require accurate tear film function assessment for treatment.
Typically, tear film evaluation follows an initial slit lamp examination. One or more surrogate markers of tear film function are used e.g., fluorescein staining, lipid layer thickness, osmolarity, meibomian gland evaluation.
These are invasive, and none of them assess the dynamic functioning of the tear film. For the clinician these multiple tests take considerable ‘chair time’, and hence cost, for the clinic staff and the patient.
Then, if dry eye disease is diagnosed, it is often an unclear diagnosis so treatment becomes an iterative process, requiring repeated evaluation of the tear film after trying each therapy option. Because of this complexity and cost to the clinic, dry eye patients are often referred to a specialist dry eye disease clinic and so are lost to the practice. Both patients and clinicians are frustrated.
TearView changes this, because for the first time the functioning of the tear film can be observed in real time during natural blinking cycles. Any tear film behaviour abnormalities, and the effects of simple procedures such as meibomian gland expression, can be seen instantly. Similarly with observing the efficacy of new eye drops.
“TearView was a revelation for me. From my perspective, I now don’t need more than a TearView exam
combined with a slit lamp assessment for a comprehensive dry eye diagnosis.”
Dr Jim Kokkinakis – Optometrist, The Eye Practice, Sydney
If an abnormality is observed with TearView, then current tests used by the clinic for dry eye can still be performed because TearView is totally non-invasive. For example, fluorescein staining could be performed to detect the extent of damage to the corneal surface.
Our TearView Technology
TearView is an ultra-sensitive photon emissivity imaging camera developed from the latest military grade technology with a bespoke lens designed for eye clinics. It records natural infrared coming from the ocular surface. This means that no light needs to be shone onto the eye and in fact, it can be used in complete darkness.
All substances naturally emit infrared, but different substances at the same temperature emit infrared to different degrees. This property allows for the first time the natural tear film of the eye to be seen as it spreads across the eye surface below it.
Continuous and easy monitoring of patient improvement under treatment is another highlight of this device. For example, TearView allows the clinician the ascertain the short term (e.g. directly after application) and long term effects of eye drops or contact lenses on the patient’s tear film. TearView will therefore be the new device of choice for the primary triaging assessment of the complete surface of the eye that allows any ophthalmic clinician to determine whether a tear film is functioning effectively or not.
TearView® Clinical Video Studies
Example – Normal Tear Film
Patient 1: Barely Spreading
Patient 2: Dry Eye Partially Spreading
Patient 2: Dry Eye Partially Spreading Fluorescein
Patient 3: Break-Up Dry Eye
Patient 4: Dry Eye No Tear Film
Meibum Release
A frame from TearView® video of a patient with faulty tear
films in each eye (dark areas with no tear film coverage)
